Ondansetron Kalceks

Ondansetron, the active ingredient in Ondansetron Kalceks, is a 5‑HT3 receptor antagonist presented as a tablet for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery, and is authorized for distribution within the European Union market.

GNH USA supplies Ondansetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: reduces incidence and severity of nausea and vomiting in cancer patients receiving cytotoxic therapy. - Radiation‑induced nausea and vomiting: helps control nausea associated with abdominal or pelvic radiation. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures.

Common Side Effects: - Headache: mild to moderate pain often reported. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm disturbance. - Severe allergic reaction (anaphylaxis): swelling, rash, breathing difficulty. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heartbeats. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, consider the following precautions: - Cardiac assessment: evaluate risk of QT interval prolongation. - Electrolyte balance: correct hypokalemia or hypomagnesemia. - Concomitant QT‑prolonging drugs: avoid combined use when possible. - Hepatic impairment: dose adjustment may be required. - Pregnancy considerations: discuss risk‑benefit with prescriber. - Store at room temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of cardiac arrhythmia. - Apomorphine: can cause severe hypotension and loss of consciousness. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may lower ondansetron plasma concentrations. - Anticholinergic agents: may diminish antiemetic efficacy.